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Almost 30 years have passed since the first serious 
attempts at cadaveric renal transplantation, which is now 
a common occurrence. Bv 1984. more than 60.000 renal 
transplants ha~ been pertormed. Although the surgical 
technique is now standardized. methods of immuno-
suppression have continued to change from body irradia-
tion in the beginning (1,2). to 6-mercaptopurine (3). then 
azathioprine alone (4) or together with steroids (5), and 
finally cydosporine (6) as a single agent (7) or in combi-
nation with steroids (8-11). Polyclonal and. recently. 
monoclonal antilymphocyte antibodies have been used 
to supplement, conventional therapy for treatment of 
severe acute rejection (12-14). 
Increased awareness within the medical profession and 
among the general public of the improved graft survival 
being o~ined with current methods of immunosuppres-
sion has mcreased the number of patients with end-stage 
renal ,disease seeking transplantation. Although organ 
donation has also mcreased. supply continues to fall short 
of need. c~h~rmoreK there is an ever-increasing pool of 
patients With high levels of preformed cytotoxic antibody 
for. whom it is difficult to firld a suitable organ donor. 
This. more than any other factor today, determines 
whether or not-an organ transplant can be performed on 
an individual in a reasonable amount of time. 
The technical aspects of kidney transplant surgerY are 
such that the procedure can be safely performed by any 
well-trained surgeon. However, organ procurement sur-
gery, particularly the ever more frequent multiple organ 
procurement. remains an area in which insufficient train-
ing, outdated technique. and inflexible personal habits 
can jeopardize the quality of renal allografts and, at the 
same time, the viability of other retrievable organs. Given 
the current demand for and success of extrarenal trans-
plantations, every organ donor today must be considered 
for multiple organ donation and every transplant surgeon 
is obligated to become familiar with the requirements of 
successful multiple organ procurement. Similarly. nurses 
and physicians working in rcus must be alert to the 
possibility of organ donation and skilled in the care of 
the multiple organ donor. Surgical techniques have been 
developed for early in situ cooling and en bloc removal 
of the kidneys with minimal dissection in the brain-dead 
cadaver donor. These methods allow the safe removal of 
extrarenal organs without compromising the quality of 
the renal allografts (15-17). 
1322 
Today. very few renal transplant recipients I 
admissi,on to the rcu. However. postoperative reqaire 
ment ot the renal transplant recipient continues t:anap. 
special skill and judgment; serious complicati f'I!qaia 
though infrequent. require i~tenslve care. The tra°~ , 
surgeon must contmu~ as ,Pnmarv physician in the ?pera~lve penod. working 10 collaboration with spea:: 
10 cntical care ~nd nephrolo~KI The training of the trant. 
plant s~rgeon 10cludes all dlsop~1les relating to the ~ 
of the Immunosuppressed surgtcal patient such as ... 
munology, infectious disease. electrolyte and acid-but 
phYSiology, respiratory care. nutritional support, and 
1Oterpretation of dIagnostic tests including biopsies ..... 
dear and CT scans. and ultrasonography. 
This chapter will describe the current practices of thI 
renal transplantation program at the University of PlhI-
burgh. This experience is almost entirely limited to CI-. 
daveric renal transplantations. In our "opinion. direct 
crossmatch between donor cells and recipient serum Ia 
conjunction with cyclosporine-steroid therapy givesn-o 
suits good enough that the use of living related donora 
is justified only in special circumstances. Other centaI, 
however, continue to use living related donors ~:uKlluty 
because of the shortage of cadaver donors. 
PRETRANSPlANT EVALUATION AND MANAGEMENT 
Candidates for renal transplantation are first seen ' 
evaluation clinic. where a thorough history is obtained 
and a physical examination is performed. l.pboratory and 
diagnostic tests. including liver function tests. hepa.titil 
screen. blood type and HLA A. B. and DR tissue ~ 
panel reactive antibody. viral serology, ECG, chest and 
abdominal films. and voiding cystourethrogram ale 0b-
tained. Psychiatric and social worker evaluations ale aIIo 
routinely performed. and potential candidates from other 
dialysis centers are evaluated by our nephrologIsts. Oth;n 
specialty consultations are obtained as necessary· 
diabetic patients receive a stress thallium test ~ I . 
cardiology consultation. Coronary angiography 15 c»-
tained only if need is suggested by the results of ~ 
stress thallium study and upon the recommendation 
the cardiologist. is 
Once the evaluation phase is comp~etedI each c:ase « 
reviewed by a transplantation committee cons15bn81aat 
surgeons. nephrologists, social workers. and transp 
nurse coordinators. Waiting time to receIve a~ 
varies from a few months to several years. d~pen th ~K ; 
the amount of preformed cytotoxiC anttbOd\, heal pies . 
tus, and availability of allografts. Fresh serumf ~ 
are obtained each month for measurement 0 F&;D 
reactive antibodies (PRA) to a panel of lymphocytes ~ 
randomly selected individuals and for donor~~ wiIb 
crossmatching as organs become available. Patte t btood 
high levels uf antibody or with a history of receople (Gi-
transfusion are crossmatched with a serum sam 
lectcd on the day of transplantation. 
,1Jmiss 
djatelv wei 
cyclosporm 
~t :\-ray 
cultures an 
peeessary, 
~nand tl 
dialysis. th. 
physical ex 
/'I'Ompt alk 
IIOt be· reli 
not to dial 
~antationK 
pteopera tl \ 
surgery WI 
wound. 
A cleans 
Deus can b 
of a (( 
outp 
first 24 
on the 
readings (r 
boluses. d. 
OUtput am 
lerum albt: 
Iein fractio 
FlUid chi 
With oligul 
lIrgen t dia, 
in b 
lleeded. it 
. POstoper 
1111/2 nom 
protocol: (i' 
lrr\ount; (b 
lrr\ount; 0: 
lrr\ount pit 
> 
ptlfPAIlAflO.N FOR OPt:RAIION 
On .,dmillsion tor tmnllplantatilln, th~ p".tient is imme~ 
ciiately w~ighed and );iven .to ornl dose ut 17.5 mwk" ot 
cydosporin~K ooutm~ blood ~ounts and ~hcmlstnesI a 
chrit x-ray, and ECG are done, a~d specimens for vir~l 
cultures and titers are collected. Dlalvsls IS performed If 
necessary, based on the ;ud~ent of the transplant sur-
~n and the nephrologist. qh~ time lapsed since the last 
dialysis. the serum K >. and eVidence ot t1uld overload on 
hy·sical examination or chest x-ray are important factors. ~rompt allograft function is difficult to predict and should 
not be· relied upon in making the decision whether or 
not to dialyze the recipient immediately prior to trans-
plantation. If there is any doubt. it is better to perform 
preoperative dialysis, since dialysis within 24 hours after 
surgery will frequently result in bleeding in the surgical 
wound. 
A cleansing enema is then given, since postoperative 
ileus can be considerably more threatening in the pres-
ence of a colon loaded with feces. Intravenous cefazoline 
is administered on call to the operating room. After the 
induction of anesthesia. a Foley catheter is placed into 
the bladder, which is then distended with 100 to 150 ml 
of 0.25% neomycin solution to sterilize the bladder and 
facilitate implantation of the ureter. 
Use of heparin during the period when the iliac vessels 
are crossclamped for anastomosis to the kidney is at the 
discretion of the operating surgeon. Most of our surgeons 
do not use heparin routinely. Just prior to the completion 
of the vascular anastomoses and revascularization of the 
allograft. 1 gram of methylprednisolone is given intrave-
nously; mannitol or furosemide is administered by the 
anesthesiologist, under the surgeon's guidance. depend-
ing on the central venous pressure (CVP) and venous 
turgor. The allograft is then placed in a suitable position 
and the transplant ureter is implanted into the recipient 
bladder. After a final inspection for complete hemostasis 
and proper poSition of the graft. the wound is closed. 
Drains are not routinely used. 
IMMEDIATE POSTOPERATIVE MANAGEMENT 
Fluid Management 
After surgery, the patient remains in the anesthesia 
recovery unit until stable and alert. usuallv 2 to 3 hours. 
Urine output and CVP are measured everv 2 hours for 
the first 24 hours, then once each nursing shift. Depend-
ing on the initial response of the graft and on the CVP 
readings (maintained between 10 and 15 em H20), fluid 
boluses, diuretics, or both are given to support urine 
output and preserve urine flow. In patients with low 
serum albumin levels, salt-poor albumin or plasma pro-
tein fraction may be effective. 
Fluid challenges must be done with restraint. Patients 
with oliguria can easily be overloaded and then require 
urgent dialysis. Early dialysis after transplantation may 
result in bleeding in the surgical wound; if dialysis is 
needed. it should be done with minimal anticoagulation. 
Postoperative urine output is replaced with 5% dextrose 
in 1/2 normal saline (D5112NS) according to the following 
protocol: (a) for output of >300 mllh, replace 415 of the 
amount; (b) for output of 150 to 300 mllh. replace total 
amount; or (c) for output of <150 mllh. replace total 
amount plus 40 mllh. 
Immunosuppression 
Steroids .ue be~un .1t ZOO tn!-iduv in tuur divided duses 
.md tnpered K1c~ordin~ tu the tolluwin~ scht.-dult..·: 
1. Mcthylprednisulunc 50 mg IV q () h x -i. then 
2. Prt!dnisone 40 m); p.o. q 6 h x ·t then 
3. Predmsone 30 mg p.o. q 6 h x 4. then 
4. Prednisone 20 mg p.o. q 6 h x 4. then 
5. Predmsone 20 mg p.o. q 12 h x 2. then 
6. Predmsone 20 mg p.o. qd. 
After 8 hours. uni~s the patient has an ob\ious ileus. 
tluids are started orallv and the diet advanced as toler-
ated. Cyclosporine is 'started at 17.5 mg/kg p.o. daily 
given in two divided doses. If oral fluids and medication 
are not tolerated. an equivalent dose of IV methylpred-
nisolone is substituted tor prednisone. and cvdosporine 
is given intravenously 4 to 6 mgtkg-day in t\\·o divided 
doses. 
The col~v catheter and the CVP line are discontinued 
on the second day unless circumstances require other-
wise. Complete blood count. electrolytes. blood urea 
nitrogen. creatinine. and cyclosporine trough le\"els are 
obtained daily, and the cyclosporine dose adiusted ac-
cordingly. Baseline nuclear renal flowgram and sonogram 
are obtained on the first postoperative day and are 
repeated weekly in patients with Significant graft dys-
function. 
EARLY POSTOPERATIVE COMPUCATIONS AND THEIR 
MANAGEMENT 
Rejection 
Diagnosis 
The direct crossmatch obtained prior to transplantation 
prevents most cases of hyperacute antibody-mediated 
allograft rejection. In patients with high titers of pre-
formed cytotoxic antibodies, accelerated rejection may 
still occur, occasionally with a pattern of disseminated 
intravascular coagulation (IS). Accelerated acute rejection 
is often severe and difficult to treat. Oose monitoring of 
coagulation is necessary and renal scans are obtained 
daily to check for the presence of blood flow to the 
allograft. Infarcted allografts must be promptly removed. 
Most patients will experience some degree of acute 
cellular rejection during the first 3 weeks after transplan-
tation. This will be heralded by any combination of 
symptoms and laboratory findings including malaise, 
fever. arthralgia. allograft swelling and tenderness. de-
creased urinary output, leucocytOSiS, and elevation of 
BUN and creatinine. Renal flow scans and sonograms 
usuallv show diminished flow and function (19). Ultra-
sound" should show no evidence of outflow tract obstruc-
tion. and may show graft swelling and prominence of 
the renal pyramids. 
In doubtful cases, a percutaneous needle biopsy can be 
performed. There is a significant risk of hemorrhage and 
arteriovenous fistula in the graft associated with conven-
tional needle biopsy; therefore, we do not routinely 
biopsy renal allografts. Fine-needle aspiration techmques 
recently advocated by Hayry et a1. (20-22) may be pref-
erable and safer. 
The sur~eon must be extremely alert durin~ this deli-
cate early post-transplantation phase. Cyclosporine ab-
sorption is highly variable. and careful monttoring is 
reqUired to prevent blood levels from falling dangerously 
luw .. !ntrave·nous cyciospurine shuuld be .ldded to the 
th!.!rnpy it. ural .lbsorption ut thc drug is uns.ltisfnctory. 
,IS utt!.!n happens in diabetics. Obese patients mav nlso 
reqUIre .intravenous supplementation until tat stores ,ut? 
saturated and satisfactory blood levels of cyclosporine 
Gin be maintained by oral administration nlone. 
Treatment 
Mild cellular rejection will usually be reversed with a 
single intravenous bolus of steroids (1 gram of methyl-
prednisolone in adults and 1 grom of hydrocortisone in 
children). Moderate rejection. or rejection that responds 
only partially to bolus therapy. can be treated with a 
repeat of the initial postoperative taper of high-dose 
steroid. Severe, steroid-resistant rejection or accelerated 
acute cellular rejection is best treated with a 10- to 14-dav 
course of OKT3 monoclonal antilymphocyte antibody 
(OKT3 Orthoclone[RJ, Ortho Pharmaceuticals. Raritan, 
NJ). 
OKT3 has several advantages over conventional poly-
donal antilymphocyte globulin (ALG) including ease of 
administration, higher efficacy, and fewer side-effects. 
Anaphylaxis or anaphylactoid reactions are uncommon. 
Most side-effeets occur onlv with the first few doses. and 
can often be prevented by' premedication with antihista-
mine and low-dose steroids. Our results with this therapy 
have been extremely gratifying (13.14) and there have 
been no fatal side-etfects in our experience with this 
drug. Failure of an allograft from acute cellular rejection 
is unusual with OKT3 therapy except in patients with a 
historv of severe rejection of a previous allograft. 
OKT3 is administered as an intravenous bolus bv a 
phYSician over 5 minutes at a dose of 5 ml (5 mg)' for 
patients weighing over 35 kg. and 2.5 ml (2.5 mg) in 
patients weighing less than 35 kg. Pulmonary edema was 
observed in overhydrated patients given OKT3 during 
early trials of the drug; therefore, a chest x-ray is recom-
mended within 24 hours before the start of therapy. The 
patient is premedicated with 1 gram of intravenous hy-
drocortisone 30 minutes prior to receiving the first dose 
of OKT3, and with 250 mg of hydrocortisone 30 minutes 
prior to receiving the second dose of OKT3. Other pre-
medications given each day are 25 to 50 mg of diphen-
hydramine p.o. or IV and 650 mg of acetaminophen p.o. 
or p.r. 30 minutes prior to OKT3. Epinephrine, oxygen, 
and hvdrocortisone should be available. 
Vital signs must be measured frequently for 4: hours 
after the first two injections and for 2 hours after subse-
quent doses. OKT3 is a murine globulin; a major limita-
tion of OKT3. as with polyvalent globulins, is that it can 
be given for only one course in most cases, since these 
patients form antimurine antibodies. "Rebound" rejection 
at the end of the course occurs in less than 20% of treated 
patients if cyclosporine therapy is at an adequate dose 
before the completion of antibody therapy. 
Rejection occurring after OKT3 has been given may be 
treated with steroid therapy or by adding small amounts 
of azathioprine to the daily regimen. in the range of 0.5 
to 0.75 mglkg-day. However. in our experience at least 
30% of the patients do not form antimurine antibodies. 
and mav receive OKT3 for a second or even a third time 
(unpublished data). It is important. however. not to 
Jeopardize the patient's life by excessive zeal in the 
treatment of persistent rejection. 
Acute Tubular Necrosis 
Acute tubul.lr nt!Crosis (ATN) occurs with a cert . 
quency in renal transplants; its trL'tluency is mostly Oll"ta fit.-
to the len!;th III cold ischemia (duration of starn f1! ted 
the length ot the wnrm ischemia period. if there h~F ~ 
any. during harvestmg (21-23). Other tactors contri~utin 
to A TN to .1 variable de!;ree are lengthy prelim g 
dissection in the donor. epIsodes of blood pressure ilhary 
bilitv and/or ischemia in the donor. and the presencens~ 
length of warm ischemia during transplantation pa::; 
ularly in old kidneys. • c-
Diagnosis 
The first thing to be done in the presence of anuria 0 
oliguria after renal transplantation is to establish if th: 
CVP is adequate. i.e .• 5 to 6 em e~l or greater. If it is 
low-and it generally drops conSiderably after revascu_ 
larization of the allograft. especially if the patient was 
dialyzed just prior to the operation--one or two boluses 
of intravenous t1uids should be administered over a short 
period of time. followed by intravenous furosemide. If 
no result is obtained with these maneuvers, the intrave-
nous fluid administration rate must be drasticallv reduced 
to 30 mIIh or less, lest the patient develop acute pulmo-
narv edema requiring emergency dialvsis with its danger 
of bleeding in the wound. Immediate diagnostic tests 
must be undertaken in order to rule out mechanical 
problems or accelerated rejection. Characteristicallv, the 
renal flow scan will show good flow. but poor function 
and the ultrasound with Doppler capability will demon-
strate good vascular flow in both renal artery and vem, 
as well as absence of large fluid collections. or hydroure-
ter. The renal flow scan will also be able to diagnose a 
disruption of the ureteroneocystostomy by demonstrating 
extravasation of the isotope during the delayed function 
ph~se of the study. 
Management 
Once the diagnosis of A1N has been established. the 
extremely cautious management of fluid intake and fre-
quent monitoring of serum electrolytes are of paramount 
importance. As previously mentioned, pulmonary edema 
is a real threat. as is hyperkalemia. If either of the two 
occurs. intensive care and emergency dialysis may be-
come necessary. A1N is a reversible phenomenon in 
most cases and usuallv resolves within 2 to 3 weeks, 
although it may last several months. Some centers treat 
the patients with steroids. azathioprine. or antithymocyte 
globulin or monoclonal antibody preparations for 1 w~k 
to 10 days. or until the resolution of the problem. addmg 
cyclosporine to the regimen only when the A TN has 
resolved. At our center, we maintain the cyclosponne 
doses unchanged, since most A1N cases resolve anyway 
(although possibly over a slightly longer period of tune) 
and cyclosporine's immunosuppressive properties are 
advantageous. 
Infection 
Infection remains a constant threat in the immunosUP-
pressed patient. The danger is particularly acute durin~ 
the early postoperative period of hil;h-dose sterOId an 
cydosporine therapy. Infection is the most common cause 
of patient mortality after renal transplantation, and IS 
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:"'UP1I'reSSIC)n: The highest index of suspicion and Kl~­
treatment are required to prevent and combat 
Fever or other symptoms of infection should be 
:"'rr,ec1:.a[l!!iY investigated and C&1n never be dismissed as 
Bacterial infections present either as 10000lized (wound. 
i_ •• nl!!onnt:. intrarenal. urinary infection), or originating 
systems (lungs. meninges. intra-abdominal. 
. Either may present with bacteremia and septic 
The organisms are often Gram-negative rods. 
resistant to many of the common antibacterial 
or esoteric organisms rarely found except in 
lillunwfllprplpre!ppb~ patients. Streptococcus faecalis. Pseu-
aeruginosa. Herellea. SerratiJz. Morganella morgagni. 
monocytogenes, and Legionella pneumophila are the 
common infective agents. If infection is suspected. 
Iltultiple cultures are obtained and polyantimicrobial ther-
apy is instituted without delay, even before the culture 
results become available. Patients in shock belong in the 
lCU, where careful monitoring can be accomplished and 
performed at the first signs of impending 
respiratory failure. If the source of infection is not known, 
urine. sputum, blood and spinal fluid cultures, sonogra-
phy, cr scan, and an indium-labeled WBC scan may all 
be necessary. Fluid collections detected by sonography 
or cr scan must be drained immediately, surgically or 
with drains left in place. 
rare to remove the native kidneys prior to 
transplantation. The possibility of abscesses devel-
in the native kidnevs should not be overlooked. 
scan is an extreme"iy valuable tool in their detec-
Advice from the infectious disease consultants can 
very valuable, particularly in detecting sensitivity to 
drugs or unusual combinations of antibiotics. 
Pneumocystis carinii and Legionella pneumophila pneu-
.,norrias are uncommon in most surgical patients, but are 
the most frequent causes of pneumonia in the 
patient. Dyspnea and hypoxemia 
prE!CeCle significant changes in the chest x-ray. Bron-
~:1yMRiClg:1s bronchoalveolar lavage (BAL) should be 
.-J:lenom:ted as soon as possible in order to confinn the 
Therapy with intravenous trimethoprim-sul-
atauu!thclxa2:ole (Bactrim) and erythromycin should be 
. as soon as pneumonia is suspected without wait-
Illg for the results of diagnostic studies. Therapy can later 
~ modified once the offending organism has been iden-
tified. Delay in treating Pneumocystis or Legionella pneu-
. can be lethal. Even in the presence of a negative 
diagnostic study. if the clinical course is typical of Pneu-
CIlrinii pneumonia or Legionnaire's disease, ther-
be continued. 
with Bactrim frequently results in the elevation :u ~ creatinine levels, which is reversible when the 
. ~ IS reduced or withdrawn. Bactrim toxicity can be 
distinguished from cyclosporine toxicity and rejection by 
:proPriate mOnitoring of cyclosporine blood levels and 
111 e USual diagnostic tests for rejection (nuclear flow scan. 
trasound. and occasionally biopsy). 
. Pa.tients with Pneumocystis CIlrinii pneumonia often need 
~tilatory support. The clinical findings often seem 
~llar to acute respiratory distress syndrome (ARDS). It 
~ therefore tempting to improve oxygenation by increas-
,llIg POsitive end-expiratory pressure (PEEP) and keeping 
the concentration of inspired oxygen relatively low, while 
hydrntin~ the patient to maintOlin K1diDquat~ v~nuus re-
turn. We believe thOlt hi~h yFxy~n L'Oncentrntilln for a 
tew days. in conjunction with relatively low PEEP and 
conservative use of tluids. is more effective and sater. 
since the potential oxygen toxicity is balanced by the 
benefits of improved cOlrdiilC pertormance and a\'(lidance 
of pneumothorax and pneumomediastinum from pul-
monary "blow-out." 
We recommend prophylactic therapy with trimetho-
prim-sulfamethoxazole tor all patients tor 6 months after 
transplantation. One singie-strength tablet taken at bed-
time affords significant protection from Pnellmocystis 
pneumonia and usually does not significantly raise serum 
creatinine. Patients who are allergic to sulfa drugs can be 
given trimethoprim alone. 
Fungal 
Fungal infections. although uncommon, also occur with 
higher frequency than in nonimmunosuppressed pa-
tients. NoazrdiJz asteroides or Cryptococcus neojormans can 
cause pneumonitis or meningitis that may remain quite 
indolent ,for long periods of time. leading to progressive 
deterioration of the patient and possible death. undidll 
infection may complicate wound hematomas or rupture 
of the kidney, and may also cause disabling GI infection 
such as severe esophagitis. Mycostatin oral suspension 
("swish and swallow") is given four times daily tor 3 to 
6 months after transplantation to reduce the risk of oral 
and esophageal candidiasis. Amphotericin Band S-fluo-
rocytosine are given intravenously for major systenuc 
monilial infections. 
Viral 
In our experience, bacterial infections are better tolerated 
and usually easier to treat in patients treated with cycle-
sporine and low-dose steroids than in patients treated 
with conventional azathioprine and high-dose steroid 
therapy. However, viral infections remain a common and 
dangerous problem, even with cyclosporine therapy. The 
agents most frequently involved are cytomegalovirus 
(CMV), herpes virus (HV). and Epstein-Barr virus (EBV). 
Localized herpes lesions can be treated with topical 
and oral acyclovir, but more extensive mucocutaneous 
lesions and- generalized herpes require treatment with 
intravenous acyclovir. Patients with normal renal function 
are given 10 mglkg every 8 hours. The dose should be 
adjusted to the current level of renal function. 
SystemiC infection with CMV may present with mal-
aise. fever, possibly cough and shortness of breath. 
elevation of liver enzymes. leucopenia, and atypicallym-
phocytes on peripheral blood smear. EBV has been as-
sociated with the development of pseudolymphomatous 
lesions, as discussed below. 
Treatment of all major infections should include reduc-
tion or even cessation of immunosuppression, particu-
larly steroids, without which therapy will be ineffective 
or incomplete. For the renal transplant recipient. graft 
loss can be managed by returning the patient to dialysis. 
Uncontrolled sepsis means death. 
Vascular Complications 
Atterlal 
Arterial complications (thrombosis and disruption) are 
almost invariably technical in nature. The only notable 
exccption is that (It arterial thrombosis in accclernh.-u 
reje!ction. in which intrnrenal arteriolar thrombosis leads 
to increased vascular resistance. diminished tlow. and 
subsequent occlusion ot the fa~r vessels. 
Acute oliguria or anuria following an initial postoper-
ative period of good grnft function must be considered 
as an indication that an acute vascular accident. either 
arterial or venous. has occurred. The patient may com-
plain of acute pain over the groft; grnft tenderness and 
hematuria are common findings. With arterial thrombo-
sis. the graft may not be swollen. The patient should be 
taken to the operating room promptly tor exploration. 
Occasionally. an arterial vascular accident can be sal-
vaged. but usually allograft nephrectomy is required. 
Disruption of the arterial anastomosis is quite rare. It 
is heralded by sudden onset of excruciating pain in the 
area of the allograft. swelling. cessation of urine output, 
and signs of hypovolemic shock. The disruption of the 
anastomosis may behave like a dissecting aneurysm. with 
periods of tamponade and stabilization in between re-
bleeding and enlargements until the final. catastrophic 
rupture. In these patients. the first episode of acute pain 
may be erroneOUSly attributed to acute rejection and 
treated with steroid boluses (24.25). A sonogram is often 
diagnostic and a renal flow scan may demonstrate extrav-
asation during the perfusion phase. Disruption of the 
vascular anastomosis is a life-threatening event requiring 
emergency exploration. allograft nephrectomy. and. if 
feasible, repair of the iliac artery. If the iliac artery cannot 
be repaired. it can often be ligated without the necessity 
for grafting. In the exceptional case in which grafting is 
reqUired, we have used arterial homografts when avail-
able (26). Synthetic prosthetic materials are contraindi-
cated for local in situ repair. since the wound is often 
invaded by Ozndida species. Serial sonograms are used to 
monitor for the development of pseudoaneurysms. In the 
unusual case in which extra-anatomical bypass of the iliac 
artery has to be undertaken. it can usually be deferred to 
a later operation and synthetic materials can be used. 
Venous 
yenous thrombosis is a relatively rare complication. and 
It IS usually due. to kinking of an improperly positioned 
allograft. excessive stretch on a short vein. or other 
technical fault in reconstruction of the renal vein. Throm-
bosis of the allograft renal vein presents with severe pain. 
s:welling. diminished urinary output. and gross hematu-
na. Allograft nephrectomy is always necessarv. 
The left renal vein is usually of sufficient length so that 
it is easy to implant. If the vena cava has been left 
attached to the right renal vein. it can be used to add 
length. or free grafts of donor iliac vein can be used. Less 
attractive but sometimes necessary alternative reconstruc-
tions involve anastomosis to the proximal end of a divided 
internal iliac or. in cases of extreme difficulty. external 
iliac vein. In rare instances. thrombosis of the renal vein 
may occur in conjunction with an occlusion of the entire 
femora-iliac axis in the recipient. We have not seen the 
latter .. ~espite the fact that we do not employ systemic 
hepanruzabon dunng the crossclamping phase. 
Rupture of Allograft 
Rupture of the transplanted kidney can occur during 
episodes of acute rejection in which there is sudden and 
severe swellily~ llt the! o~alyK ::Fln~Kc tne Introdu . 
I..--yclosponne. such severe acute rel~"tion epiSOd Ction of 
become rorer. They occur preciomirulntlv on th es ~ve 
border, in a plane between lobar arteries. pro~a:nvn 
area of decreased resistance. Rupture pt"esentst Y an 
sudden onset of pain and swellin~ of the allo W1 ~ the 
well as signs of occult bleeding. A renal flow grn t, as 
show extravasation of controst material dUrin srK:~ may 
fusion phase. but it may be difficult to distingu~h e per-
asation from allograft rupture and vascular anastextrav-
dehiscence. Immediate surgical exploration is ind~::::::D 
Small fractures may be repairable with absorbable sutu 
andior hemostatic materials. while larger ruptures requ':: 
nephrectomy. usually total (27). Chronicallv ruptured 
kidneys surrounded by clot are invariably colOnized by 
fungi. 
Urological Compllcattons 
Ureteral Ischemia 
Urological complications are always the result of technical 
errors. occurring during either harvesting (and "back 
table" work) or recipient operation. Sloughing of the 
donor ureter is secondary to disruption of the blood 
supply to the ureter. which receives all its flow from the 
donor renal artery. In most instances. severance of a low 
polar artery is the culprit. but "stripping" of the ureter 
during preparation of the allograft may accomplish the 
same thing. Dissection between the kidney and ureter 
that is carried proximally to the horizontaf line passing 
the lower pole of the kidney should immediatelv raise 
suspicion of injury to the ureteral blood supplv: After 
revascularization. the ureter should be carefullv observed 
for color changes and venous turgor. and. at the time of 
trimming for the ureteroneocystostomy, cutting across 
without hemostasis will show if the bleeding is brisk 
enough. If there is any doubt as to the viability of the 
distal ureter. a ureteroureterostomy or ureteropyeloneos-
tomy using the recipient's ipsilateral ureter should be 
done. In this event. the ipsilateral native kidney should 
be removed. 
Ureteral necrosis after transplantation usually presents 
with hydroureter and urinary leak. Leg and testicular (or 
labial) swelling and drainage of fluid from the wound are 
signs of a possible urinary leak. Ultrasound and flow 
scans help determine the diagnosis. Percutaneous ne-
phrostomy or internal stenting can be used to control 
drainage; some injuries will heal if well drained (28-30). 
In addition. such measures can aid in definitive repair. 
Ureteroureterostomy of proximal donor ureter or ureter-
opyeloneostomy to distal recipient ureter over an internal 
stent can be done to salvage the graft. combined with 
ipsilatezal native nephrectomy. The ureteral stent is then 
removed cystoscopically after 6 weeks. 
Ureteral StenosiS and Obstruction 
Stenosis may occur at the ureteroneocystostomy due to 
incorrect suturing. crushing of the delicate ureteral tissue 
with sutures or forceps. or by strangulation inside the 
submucosal tunnel. It also may occur at higher levels m 
the ureter. secondary to compression by the testicular 
cord structures in males or the round ligament in females. 
or by the inferior epigastric vessels. if not tied a~d 
divided. Surgical intervention is usually necessary In 
order to correct these problems. although percutaneous 
nephrostomy also has been useful (29.30). 
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ClUTlCAL CARE IN KIDNeY TRANSrl./\NTATION 
LyinPhOCfJIe 
,ugarion of the tissu~ covering th~ recipient's iliac vessels 
during skeletoniZ<ltion is the sat~~Kt .way to p~e~ent Iym-
hoceles. Diathermy may be sutttclent. but It IS not as ~fiableK Ureteral obstruc:tion by a lymphocele usually 
presents during the tlrst 3 months atter transplantation 
with increased BUN ,md creatinine. decreased urine vol-
ume. and a mass etfect. Sonography shows hydrone-
phrosis and fluid collection. Marsupialization of the lym-
hocele via "peritoneal window" pertormed through an ~traperitoneal approach allows. drainag~ of the fymph~­
cele into the free peritoneal cavIty to reheve the extnnslc 
compression of the ureter. It is tempting to treat obstruct-
ing lesions by percutaneous needle drainage. but the 
lesions almost always recur quickly and may become 
infected. Percutaneous sampling may be useful for diag-
nostic purposes to rule out other lesions such as an 
abscess or urinoma. 
Ileus 
ileus is almost always present in the immediate postop-
erative period as a result of the retroperitoneal dissection. 
It usually resolves rapidly, but it sometimes requires 
repeated enemas and cathartics, as well as nasogastric 
decompression. It is more frequent and troublesome in 
diabetic patients and after long operations. It is important 
to prepare patients for renal transplantation with a large-
volume enema in order to have a relatively empty colon 
during and after surgery. 
Massive colonic dilatation (Ogilvie's syndrome) is a 
serious complication that may result in bowel wall necro-
sis and spillage. and may require hemicolectomy. Ag-
gressive use of enemas and decompression colonoscopy 
is indicated. If these measures fail, decompression colos-
tomy is required. If bowel perforation occurs, colectomy, 
ileostomy, broad-spectrum antibiotics. and reduction or 
withdrawal of immunosuppression are indicated. 
Hypertension 
.Hypertension is common in patients with end-stage renal 
· disease, and is aggravated by cydosporine and the high-
dose steroids taken after transplantation. Hypertension 
is the most frequent indication for admission to the ICU 
· ~rgy after surgery and may be severe enough to result 
III cerebrovascular accidents. pulmonary edema. heart 
failure. or myocardial infarction. Treatment requires con-
· tinuous arterial pressure monitoring in the lCU. Intrave-
nous labetalol (given intermittently in doses of 20 mg 
first, then 40 mg every 10 to 15 minutes until blood 
pressure is controlled or a total of 300 mg has been 
reached, or as a continuous drip. 1 to 2 mglmin), hydral-
azine, or nitroglycerin can be be used to bring the blood 
pressure under controL Nitroprusside should usually be 
avoided because of the potential for cyanide toxicity in 
patients with renal failure. Fluid overload should be 
treated with vigorous diuresis. if possible. or dialysis. 
~osporine TOXicity 
Cyclosporine toxicity may be difficult to differentiate 
clinically from rejection. Additional tests such as renal 
~ow scans and needle biopsy may be necessary to estab-~h a diagnosis. Severe toxicity can rapidly lead to renal 
failure with fluid overload, hyperkalemia. and renotu-
buiar acidosis. Patients with cydosporine toxicity and 
13:7 
t1uid u\,crluild may ~FEplK!rilK!nce seizures nDlKlllirin~ trc.,t-
m~nt with dilantin Ilr barbiturat~sK In seyDlDrtK~ cases. pa-
tients 1l\;\V retluire admission to the lCU tor munitunng 
and respiratory support. Cyclosporine is drastically re-
duced or even stopped temporarily, and rejection is 
managed with alternative therapy with .,zathiopnne or 
monoclonal antibody. 
A different form" of cydosporine toxicity. which is 
uncommon and more prone to occur in elderly patients. 
presents with progressive confusion and e\'en delirium. 
Cydosporine must be withdrawn until the sensorium 
clears and can be reintroduced slowly once symptoms 
have subsided. 
Pancreatitis 
Pancreatitis after renal transplantation can be catastrophic 
and progress rapidly to multiorgan failure and death 
within a few davs. More often the course is less rapid. 
but no less lethal. with only a gradual deterioration and 
progression to sepsis. If the patient survives. it is often 
possible for the allograft to be saved by reintroducing 
immunosuppression once the situation has stabilized. 
The patient should be treated in the lCU with appropriate 
cardiorespiratory monitoring and support; immuno-
suppression should be stopped. Allograft rejection is 
suggested by platelet and fibrinogen sequestration and 
graft swelling. and requires graft nephrectomy. 
Fortunately, severe pancreatitis after kidney transplan-
tation has been uncommon in our experience since the 
change from azathioprine-high dose prednisone to cydo-
sporine-Iow dose prednisone therapy. We have had only 
two cases, with one death. 
lATE COMPUCATIONS THAT MAY REQUIRE 
INTENSIVE CARE 
Infection 
Although the incidence of infection decreases rapidly 
after 3 to 6 months post transplantation, life-threatenirtg 
infections do occur and need special care. The most 
frequent and dangerous agents in late infections are 
Pneumocystis carinii, Legionella pneumophila, CMV, EBV, 
fungi, varicella-zoster virus, and tuberculosis. All these 
infections require severe reduction or cessation of im-
munosuppression. and admission to the lCU is often 
necessarY. Specific agents, if available, usually must be 
used at or above the maximal dose (acyclovir. amphoter-
icin 6, 5-fluorocytosine, trimethoprim, zoster immune 
globulin, etc.). 
Rejection 
Acute rejection is quite unusual late after transplantation 
if immunosuppressive therapy has been maintained. 
Diarrhea and drugs, both of which may interfere with 
cyclosporine absorption. and patient noncompliance are 
the most frequent reasons for inadequate therapy. Inten-
sive care is rarely required except for the complications 
of increased immunosuppression. 
Lvmphoproliferative Disorders 
An increased incidence of post-transplant lymphoprolif-
erative disorders (PTLDs) has been described with all 
forms of immunosuppression, but has been seen more 
frequently since the introduction of cydosporine (31-33). 
PTLDs 'usUally uccur during th~ tlrst pust-tr.mspl<lnt year. 
The patients may present with fever. wlDi~ht luss. and/ur 
lymphadenopathy. ei~h titers of antibudy to EBV <Ire 
tUUfld .lOd positive EBV ,""Ultun.'5 em b~ ubtained in m<lny 
pMients. ~pecially those treated with ,"yciospnrinc. The 
dis~as~ may be mono- or polydonal. Lymph node <lnd 
tonsill.uy biopsy may be helpful. but tonsil biopsies may 
result in serious complications of which acute respir<ltory 
distress is the most life-threatening and requires intensive 
care. intubation. and respiratory support. 
The treatment of choice is reduction of immuno-
suppression. which will usually lead to total remission of 
the disease (34). Occasionally. debulking of large lym-
phomatous masses such as infiltrating and obstructing 
lesions in the intestinal tract may be necessary. The 
temptation to treat with chemo- or radiation therapy 
while maintaining immunosuppression should be re-
sisted. 
Hypertension 
The management of hypertension early after renal trans-
plantation has been discussed above. Chronic rejection. 
recurrence of the primary renal disease, or noncompliance 
with medication may cause attacks of acute severe hy-
pertension of an extreme degree. Rarely, late bilateral 
native nephrectomy is required for control. Allograft renal 
artery stenosis is now a less frequent cause of post-
transplant hypertension, since today it is common to use 
end-to-side techniques of arterial anastomosis in which a 
Carrel patch of donor aorta is sewn to the side of recipient 
iliac arterv. Stenotic lesions that occur distal to the renal 
artery origin may be successfully treated by balloon 
angioplasty. Lesions at the renal artery orifice are often 
less amenable to balloon dilatation because they often are 
the result of atherosclerotic disease in the wall of the 
native iliac artery. 
CONCLUSION 
For most patients experiencing renal transplantation to-
day, recovery is rapid and relatively uneventful. A brief 
stay in the postanesthesia recovery unit is followed by a 
7- to 14-day recuperation on the regular hospital floor. 
The trend in today's cost-conscious environment is for 
early discharge with close follow-up in the outpatient 
clinic. Although most patients will experience some al-
lograft rejection, it is usually responsive to therapy with 
steroids or antilymphocyte antibody. Only a small per-
centage of patients experience side-effects or complica-
tions severe enough to warrant admission to the lCU. 
Acute fulminant rejection with allograft rupture, severe 
pancreatitis, and death from bacterial sepsis are now 
uncommon. HypertenSion is the most frequent indication 
for invasive monitoring and intensive care. Viral and 
opportunistic infections remain a significant threat, but 
mortality from infection after renal transplantation is now 
less than 5%. 
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